labor team will handle all logistics and wet lab analysis for Stockholm3 in Switzerland, granting Swiss healthcare providers and patients access to Stockholm3 for early detection of prostate cancer. Known for setting new standards in laboratory medicine and offering customized analyses for individual requirements, labor team will leverage their marketing team, sales force, and logistics to deliver Stockholm3 nationwide, ensuring that men across Switzerland can benefit from this innovative testing solution.

“With our mission of making Stockholm3 the standard of care in prostate cancer diagnostics, we are thrilled to partner with labor team. Their commitment to innovation, transparency and individual diagnostics aligns seamlessly with our goal to transform prostate cancer detection,” says Martin Steinberg, Executive Chairman of A3P Biomedical.

“This partnership enables us to address an urgent medical need, providing Swiss men with an accurate and reliable diagnostic test to improve prostate cancer outcomes,” says Alain Cahen, CEO of labor team.

As prostate cancer remains the most common cancer among men, early detection and appropriate risk stratification are critical to optimizing treatment and improving survival rates. Stockholm3 combines genetic, protein, and clinical markers, enabling a far more precise assessment of prostate cancer risk than standard PSA tests. Studies show that Stockholm3 detects 41-89% more cases of aggressive cancer while reducing unnecessary biopsies by 37-52%.

With this partnership, A3P Biomedical and labor team are advancing their shared vision to improve diagnostic options and healthcare outcomes for men in Switzerland.

For more information about the Stockholm3 test, please visit www.stockholm3.com

For more information on how to access Stockholm3 in Switzerland, please contact labor team at +41 71 844 45 45.